Quotient Clinical at AAPS 2013
6 November 2013 | By kdm communications limited
Quotient Clinical – the pioneer of Translational Pharmaceutics™ – will be showcasing the benefits of its unique, integrated approach to formulation development...
List view / Grid view
News
GSK announces data to support Cervarix® two-dose schedule for the prevention of cervical cancer in 9-14 year old girls
4 November 2013 | By GlaxoSmithKline
The results showed that the two-dose schedule in girls aged 9 to 14 years old induced immune responses...
Cancer Research Technology and Nuevolution sign multi-target deal to seek potential cancer drugs
4 November 2013 | By B3C Group GmbH
The collaboration aims to identify drug leads that block the activity of a number of challenging cancer therapeutic targets....
Roche and Polyphor join efforts to combat multi-drug-resistant bacterial infections
4 November 2013 | By Roche
Roche will make an upfront payment of CHF 35 million to Polyphor as well as payments upon reaching certain development...
Johnson & Johnson and its Subsidiaries conclude previously disclosed settlement agreements with U.S. Department of Justice and 45 States
4 November 2013 | By Johnson & Johnson
The resolution includes total settlement amounts of approximately $2 billion to the federal government...
Gilead announces new sustained viral response data for Sofosbuvir based regimens in genotype 3-infected Hepatitis C patients
2 November 2013 | By Creston Health
“The VALENCE results demonstrate the high efficacy of a 24-week, sofosbuvir-based, interferon-free treatment regimen for genotype 3 HCV patients..."
Phase III data show Boehringer Ingelheim’s faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C
2 November 2013 | By Boehringer Ingelheim
"These data are encouraging and reinforce the potential benefits of faldaprevir* as an effective treatment..."
New data presented by Mundipharma highlights a portfolio with cost efficient therapies
2 November 2013 | By Portland Communications
"Mundipharma recognises the current economic environment and resulting budget constraints for healthcare systems..."
Simeprevir administered once daily as part of combination therapy demonstrates sustained virologic response in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C adult patients
2 November 2013 | By Janssen R&D Ireland
“The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option..."
Merck announces presentation of interim data from study of investigational combination of HCV therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases annual meeting
2 November 2013 | By Merck
Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied...
BMS submits first all-oral, interferon-free and ribavirin-free treatment regimen for regulatory review in Japan for patients with chronic hepatitis C infection
2 November 2013 | By Bristol-Myers Squibb Company
"We are pleased to be one step closer to bringing a potential new treatment option to the many people living with HCV..."
Incivo®(Telaprevir) data to be presented at AASLD and ISPOR on the anit-viral response, safety, tolerability and cost-effectiveness of an Incivo based regimen in the treatment of genotype-1 chronic hepatitis C
1 November 2013 | By Janssen
Janssen continues to undertake clinical studies with telaprevir to identify opportunities to serve specialized and hard-to-treat patients...
Novo Nordisk receives FDA approval for FlexTouch® in the US
1 November 2013 | By Novo Nordisk
FlexTouch® is the latest innovation in prefilled insulin delivery systems from Novo Nordisk...
Novo Nordisk increased operating profit by 10% in the first nine months of 2013
31 October 2013 | By Novo Nordisk
Sales growth of 8% driven by Victoza®, Levemir® og NovoRapid®...
Marc Dunoyer appointed Chief Financial Officer of AstraZeneca
"Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience..."
